SLC52A2: A Potential Drug Target and Biomarker (G79581)

Target Name: SLC52A2

NCBI ID: G79581

SLC52A2

SLC52A2: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 52 (SLC52A2) is a protein that is expressed in most tissues and cells in the body. It plays a crucial role in the regulation ofNa+ and Glucose transport in the kidney, and is also expressed in the heart, liver, and other organs. SLC52A2 has been identified as a potential drug target and biomarker due to its unique expression pattern and its involvement in several diseases, including diabetes, heart failure, and neurodegenerative disorders.

SLC52A2 is a member of the Transmembrane Carrier Family 52, which includes proteins involved in the transport of various molecules across the cell membrane. SLC52A2 is a 24kDa protein that consists of 154 amino acid residues. It has a unique expression pattern, being expressed in the kidney, heart, liver, and pancreas, but not in the brain or other tissues. SLC52A2 is also co-expressed with several other genes, including the transcription factor PIK3CA, which suggests that it may be a negative regulator of PIK3CA.

SLC52A2 has been shown to be involved in several physiological processes in the body, including the regulation of Na+ and Glucose transport. SLC52A2 is a critical transporter for the reabsorption of Na+ and Glucose in the urine, and is expressed in the kidney, heart, and liver. It has been shown to be involved in the regulation of Na+ and Glucose transport in the kidney, and is required for the normal functioning of the kidney. SLC52A2 has also been shown to be involved in the regulation of insulin sensitivity and glucose metabolism.

SLC52A2 has also been identified as a potential drug target due to its involvement in several diseases, including diabetes, heart failure, and neurodegenerative disorders. Diabetes is a global public health issue that affects millions of people, and is a leading cause of death in both adults and children. SLC52A2 has been shown to be involved in the regulation of insulin sensitivity and glucose metabolism in the body, and may be a useful target for the development of new diabetes treatments.

Heart failure is a condition that affects millions of people worldwide and is a leading cause of morbidity and mortality. SLC52A2 has been shown to be involved in the regulation of Na+ and Glucose transport in the heart, and may be a useful target for the development of new treatments for heart failure.

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are progressive neurological disorders that affect millions of people worldwide. SLC52A2 has been shown to be involved in the regulation of Na+ and Glucose transport in the brain, and may be a useful target for the development of new treatments for neurodegenerative disorders.

In conclusion, SLC52A2 is a unique and highly expressed protein that plays a critical role in the regulation of Na+ and Glucose transport in the body. Its unique expression pattern and its involvement in several diseases make it an attractive target for the development of new drugs and biomarkers. Further research is needed to fully understand the role of SLC52A2 in the regulation of Na+ and Glucose transport and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 52 Member 2

Functions: Plasma membrane transporter mediating the uptake by cells of the water soluble vitamin B2/riboflavin that plays a key role in biochemical oxidation-reduction reactions of the carbohydrate, lipid, and amino acid metabolism (PubMed:20463145, PubMed:22864630, PubMed:23243084, PubMed:24253200, PubMed:27702554). Humans are unable to synthesize vitamin B2/riboflavin and must obtain it via intestinal absorption (PubMed:20463145). May also act as a receptor for 4-hydroxybutyrate (Probable)

The "SLC52A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC52A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets